RRP-001 An open-label multi-center study of INO-3107 with electroporation (EP) in subjects with HPV-6-and/or HPV-11-associated recurrent respiratory papillomatosis (RRP)

Brief description of study

The purpose of this clinical trial is to see how well the investigational product and device combination work to treat recurrent respiratory papillomatosis (RRP) caused by Human Papillomavirus (HPV). This trial will assess possible benefits and risks of the therapy and its effect on your immune system. The study drug being tested in this trial is an investigational product called INO-3107. The investigational product will be given with an investigational device, CELLECTRA® 2000, which has not been FDA approved for sale in this country, but may also be used in clinical trials like this one. The CELLECTRA® 2000 will deliver small pulses of electricity through five (5) needles to get more of the investigational product into your muscle. Information on any side effects that may happen will be collected.


Clinical Study Identifier: s20-00291
ClinicalTrials.gov Identifier: NCT04398433
Principal Investigator: Milan R Amin.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.